Clinician and Patient Factors Associated With Long‐Term Glucocorticoid Use in People With Rheumatoid Arthritis Receiving Advanced Therapies
Authors' conclusion
Lower clinician concerns about GC, biologic, and JAKi safety were associated with greater GC prescribing
Study context
- Population
- Clinicians in the CorEvitas rheumatoid arthritis (RA) Registry, surveyed 2023–2024, and their patients with RA starting a new biologic or JAK inhibitor (JAKi)92 of 256 clinicians responded
- Outcome
- GC use after starting treatment, by patient and clinician factors
- Follow-up
- Six months
Methodological detailsmixed-effects logistic regression, adjusted for patient factors, 81 responding clinicians had 3,966 qualifying patients; 164 nonresponders had 3,196
- Mixed-effects logistic regression
- Adjusted for patient factors
- 81 responding clinicians had 3,966 qualifying patients; 164 nonresponders had 3,196
Main finding
As reported in the abstract
GC prescribing at six months by clinician safety concern (less vs more concern)
Adjusted odds ratio (95% CI)
Less concern about prednisone ≤5 mg/day
1.98(1.17–3.36)
Less concern about biologics
2.47(1.33–4.49)
Less concern about JAKi
2.35(1.31–4.22)
Observational data: associations, not effects.
Further findings
Patient factors associated with glucocorticoid (GC) use at six months
- Higher disease activity, age ≤45 or >75 years, longer disease duration, more previous biologics/JAKi, lung disease and earlier calendar year associated with greater GC use
Original publication
Clinician and Patient Factors Associated With Long‐Term Glucocorticoid Use in People With Rheumatoid Arthritis Receiving Advanced Therapies. Arthritis Care Res (Hoboken). Published 21 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →